Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment.
Neuro Endocrinol Lett. 2008 Aug; 29(4):435-7.NE

Abstract

Clozapine is an atypical antipsychotic indicated for the treatment of refractory schizophrenia. Clozapine treatment is associated with the metabolic side effects. Weight gain, hyperlipidemia and hyperglycemia are the risk factors for onset of diabetes and cardiovascular disorders. We report a case vignette of a patient in whom the decrease in negative and general psychopathology after adjunctive aripiprazole appeared simultaneously with a reduction of clozapine-induced increase in weight and metabolic measures. Combined application of clozapine and aripiprazole is in accordance with a neurobiological rationale and appears to be a safe and well tolerated.

Authors+Show Affiliations

Masopust J
Charles University in Prague, Faculty of Medicine, Czech Republic. masopustj@lfhk.cuni.cz
Tůma I
No affiliation info available
Libiger J
No affiliation info available

MeSH

AdultAntipsychotic AgentsAripiprazoleClozapineDrug Therapy, CombinationHumansMalePiperazinesQuinolonesSchizophrenia, ParanoidWeight Gain

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18766167